TY - JOUR
T1 - Sustainable return to work among breast cancer survivors
AU - Ruiz de Azua, Garazi
AU - Kousignian, Isabelle
AU - Vaz-Luis, Ines
AU - Di Meglio, Antonio
AU - Caumette, Elsa
AU - Havas, Julie
AU - Martin, Elise
AU - Martin, Anne Laure
AU - Querel, Ophelie
AU - Vanlemmens, Laurence
AU - Pistilli, Barbara
AU - Coutant, Charles
AU - Cottu, Paul Henri
AU - Merimeche, Asma Dhaini
AU - Lerebours, Florence
AU - Tredan, Olivier
AU - Jouannaud, Christelle
AU - Levy, Christelle
AU - Dumas, Agnes
AU - Menvielle, Gwenn
N1 - Publisher Copyright:
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
PY - 2023/9/1
Y1 - 2023/9/1
N2 - Purpose: This study assessed sustainable return to work (SRTW) of breast cancer survivors (BCS). Methods: We used data from the prospective French cohort, CANTO. We included 1811 stage I–III BCS who were <57 years old and employed at the moment of diagnosis and working 2 years after diagnosis. Using logistic regression, we investigated the role of clinical, health and socio-economic factors, and the work environment on SRTW 3 years after diagnosis. We compared having any sick leave with having worked continuously and being unemployed to having worked continuously between 2 and 3 years after diagnosis. Results: Overall, 77% (n = 1395) worked continuously after return to work (RTW). Out of the other 416 BCS, 66% had any sick leave period, 33% had been unemployed, 4% had an early retirement, 2% a disability and 1% another status (multiple situations possible). Being on sick leave was associated with age > 50 (OR = 0.59; 95%CI = 0.43–0.82), stage III (2.56; 1.70–3.85), tumour subtype HR+/HER2+ (0.61; 0.39–0.95), severe fatigue (1.45; 1.06–1.98), workplace accommodations (1.63; 1.14–2.33) and life priorities (0.71; 0.53–0.95). Unemployment was associated with age > 50 (0.45; 0.29–0.72), working in the public sector (0.31; 0.19–0.51), for a small company (3.00; 1.74–5.20) and having a fixed-term contract (7.50; 4.74–11.86). Conclusions: A high number of BCS have periods of sick leave or unemployment after RTW. The determinants differ between sick leave and unemployment. Implications for cancer survivors: BCS need to be supported even after RTW, which should be regarded as a process.
AB - Purpose: This study assessed sustainable return to work (SRTW) of breast cancer survivors (BCS). Methods: We used data from the prospective French cohort, CANTO. We included 1811 stage I–III BCS who were <57 years old and employed at the moment of diagnosis and working 2 years after diagnosis. Using logistic regression, we investigated the role of clinical, health and socio-economic factors, and the work environment on SRTW 3 years after diagnosis. We compared having any sick leave with having worked continuously and being unemployed to having worked continuously between 2 and 3 years after diagnosis. Results: Overall, 77% (n = 1395) worked continuously after return to work (RTW). Out of the other 416 BCS, 66% had any sick leave period, 33% had been unemployed, 4% had an early retirement, 2% a disability and 1% another status (multiple situations possible). Being on sick leave was associated with age > 50 (OR = 0.59; 95%CI = 0.43–0.82), stage III (2.56; 1.70–3.85), tumour subtype HR+/HER2+ (0.61; 0.39–0.95), severe fatigue (1.45; 1.06–1.98), workplace accommodations (1.63; 1.14–2.33) and life priorities (0.71; 0.53–0.95). Unemployment was associated with age > 50 (0.45; 0.29–0.72), working in the public sector (0.31; 0.19–0.51), for a small company (3.00; 1.74–5.20) and having a fixed-term contract (7.50; 4.74–11.86). Conclusions: A high number of BCS have periods of sick leave or unemployment after RTW. The determinants differ between sick leave and unemployment. Implications for cancer survivors: BCS need to be supported even after RTW, which should be regarded as a process.
KW - breast cancer
KW - cohort
KW - employment
KW - epidemiology
KW - quality of life
UR - http://www.scopus.com/inward/record.url?scp=85168575263&partnerID=8YFLogxK
U2 - 10.1002/cam4.6467
DO - 10.1002/cam4.6467
M3 - Article
C2 - 37602836
AN - SCOPUS:85168575263
SN - 2045-7634
VL - 12
SP - 19091
EP - 19101
JO - Cancer Medicine
JF - Cancer Medicine
IS - 18
ER -